AVIR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AVIR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Atea Pharmaceuticals's yield on cost for the quarter that ended in Dec. 2023 was 0.00.
The historical rank and industry rank for Atea Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Biotechnology subindustry, Atea Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Atea Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Atea Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Atea Pharmaceuticals is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
Atea Pharmaceuticals (NAS:AVIR) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of Atea Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Franklin M Berger | director | 1000 MARINA BLVD, STE 200, BRISBANE CA 94005 |
Polly A. Murphy | director | C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110 |
Jerome M. Adams | director | C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110 |
Cormorant Global Healthcare Master Fund, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Hack Andrew A. F. | director | 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142 |
Rock Springs Capital Master Fund Lp | 10 percent owner | 190 ELGIN AVENUE, GEORGE TOWN E9 KY1 9001 |
Jean-pierre Sommadossi | director, 10 percent owner, officer: President, CEO, and Chairman | 125 SUMMER STREET, 16TH FLOOR, BOSTON MA 02110 |
Jpm Partners Llc | 10 percent owner | C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110 |
Chung K. Chu | 10 percent owner | C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110 |
Janet Mj Hammond | officer: Chief Development Officer | C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110 |
Isaac Cheng | director | C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110 |
John Vavricka | officer: Chief Commercial Officer | C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110 |
Bruno Lucidi | director | C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110 |
Maria Arantxa Horga | officer: Acting Chief Medical Officer | C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110 |
Bruce Polsky | director | C/O VISION-SCIENCES, INC., 40 RAMLAND ROAD, ORANGEBURG NY 10962 |
From GuruFocus
By Value_Insider Value_Insider • 11-22-2022
By sperokesalga sperokesalga • 05-08-2023
By sperokesalga sperokesalga • 06-15-2023
By PurpleRose PurpleRose • 07-11-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
By Value_Insider Value_Insider • 11-29-2022
By Marketwired • 09-06-2023
By Value_Insider Value_Insider • 11-03-2022
By sperokesalga sperokesalga • 05-23-2023
By Stock market mentor Stock market mentor • 02-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.